drugset / Trial / NCT06463743
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Phase 2
Recruiting
30 enrolled
State University of New York at Buffalo
National Center for Advancing Translational Sciences (NCATS) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy. The investigators want to learn: * The safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo * How well metformin protects the nervous system against injury compared with placebo measured by brain MRI over a 9 month treatment period * The effect of metformin to protect brain tissue from age and MS related injury when compared to the placebo group over a 9 month treatment period
Timeline
- Start
- 2025-09-24
- Primary completion
- 2027-01-01
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 1500 mg | — |